Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Bone|March 6, 2021
"The use of bisphosphonates to treat skeletal complications in solid tumours"S D'Oronzo, S Wood, J E BrownCancer Treatment Reviews|September 28, 2015
Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implicationsS D'Oronzo, S Stucci, M Tucci, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 25, 2018
Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanomaM Tucci, L S Stucci, F Mannavola, et al.Journal of Bone Oncology|June 16, 2021
Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendationsJ E Brown, S L Wood, C Confavreux, et al.ESMO Open|May 13, 2021
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paperN Silvestris, A Argentiero, A Natalicchio, et al.ESMO Open|May 21, 2021
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paperM Gallo, V Adinolfi, L Morviducci, et al.ESMO Open|June 1, 2023
MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical viewA Natalicchio, M Montagnani, M Gallo, et al.ESMO Open|December 9, 2023
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paperN Silvestris, T Franchina, M Gallo, et al.Journal of Endocrinological Investigation|June 27, 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical viewA Natalicchio, N Marrano, M Montagnani, et al.Pageof 1